20.03.2014 22:04:54
|
Ambit Biosciences Q4 Loss Narrows
(RTTNews) - Ambit Biosciences Corp. (AMBI) Thursday posted fourth-quarter net los of $2.0 million, narrower than $5.1 million in the comparable quarter last year.
Total revenue for the latest fourth quarter was $1.28 million, down from $2.94 million last year. Analysts had consensus revenue estimate of $670 thousand. The decrease was primarily due to the termination of the Company's collaboration with Astellas Pharma, which occurred in September 2013.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Ambit Biosciences Corpmehr Nachrichten
Keine Nachrichten verfügbar. |